BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32003806)

  • 1. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
    Lococo F; Rena O; Torricelli F; Filice A; Rapicetta C; Boldorini R; Paci M; Versari A
    Interact Cardiovasc Thorac Surg; 2020 Apr; 30(4):593-596. PubMed ID: 32003806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
    Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
    In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
    Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of pretreatment volume-based quantitative
    Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
    Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S; Zahid I; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and predictive role of [
    Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V; Roca E; Lucchini S; Laroumagne S; Loundou A; Dutau H; Maldonado F; Astoul P
    Respiration; 2015; 89(6):558-64. PubMed ID: 25966972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loco-regional staging of malignant pleural mesothelioma by integrated
    Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
    Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the best way to diagnose and stage malignant pleural mesothelioma?
    Zahid I; Sharif S; Routledge T; Scarci M
    Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined positron emission tomography/computed tomography for diagnosis and monitoring of orbital adnexal lymphoma.
    Klingenstein A; Garip-Kuebler A; Mueller-Lisse UG; Hintschich C
    Acta Ophthalmol; 2018 Sep; 96(6):e712-e717. PubMed ID: 30146694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience.
    Cimen F; Agackiran Y; Düzgün S; Aloglu M; Senturk A; Atikcan S
    Medicine (Baltimore); 2022 Sep; 101(39):e30711. PubMed ID: 36181042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
    Pilling J; Dartnell JA; Lang-Lazdunski L
    Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
    Martini K; Meier A; Opitz I; Weder W; Veit-Haibach P; Stahel RA; Frauenfelder T
    Lung Cancer; 2016 Apr; 94():40-5. PubMed ID: 26973205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
    Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
    Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Novel Prognostic Risk Classification System for Malignant Pleural Mesothelioma.
    Doi H; Kuribayashi K; Kitajima K; Yamakado K; Kijima T
    Clin Lung Cancer; 2020 Jan; 21(1):66-74.e2. PubMed ID: 31551134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body MRI: Comparison of Its Capability for TNM Staging of Malignant Pleural Mesothelioma With That of Coregistered PET/MRI, Integrated FDG PET/CT, and Conventional Imaging.
    Ohno Y; Yui M; Aoyagi K; Kishida Y; Seki S; Koyama H; Yoshikawa T
    AJR Am J Roentgenol; 2019 Feb; 212(2):311-319. PubMed ID: 30512992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.